68 related articles for article (PubMed ID: 16222609)
21. Hyperglycaemia: the bridge between non-enzymatic glycation and oxidative stress in the pathogenesis of diabetic complications.
Ceriello A
Diabetes Nutr Metab; 1999 Feb; 12(1):42-6. PubMed ID: 10517306
[TBL] [Abstract][Full Text] [Related]
22. Hypothesis: the 'metabolic memory', the new challenge of diabetes.
Ihnat MA; Thorpe JE; Ceriello A
Diabet Med; 2007 Jun; 24(6):582-6. PubMed ID: 17490424
[TBL] [Abstract][Full Text] [Related]
23. Advanced glycation end products: sparking the development of diabetic vascular injury.
Goldin A; Beckman JA; Schmidt AM; Creager MA
Circulation; 2006 Aug; 114(6):597-605. PubMed ID: 16894049
[TBL] [Abstract][Full Text] [Related]
24. Role of vascular reactive oxygen species in development of vascular abnormalities in diabetes.
Son SM
Diabetes Res Clin Pract; 2007 Sep; 77 Suppl 1():S65-70. PubMed ID: 17467110
[TBL] [Abstract][Full Text] [Related]
25. Diabetic threesome (hyperglycaemia, renal function and nutrition) and advanced glycation end products: evidence for the multiple-hit agent?
Kanková K
Proc Nutr Soc; 2008 Feb; 67(1):60-74. PubMed ID: 18234133
[TBL] [Abstract][Full Text] [Related]
26. Inhibitors of advanced glycation end product formation and neurovascular dysfunction in experimental diabetes.
Cameron NE; Gibson TM; Nangle MR; Cotter MA
Ann N Y Acad Sci; 2005 Jun; 1043():784-92. PubMed ID: 16037306
[TBL] [Abstract][Full Text] [Related]
27. [Lipoprotein glycation and glycoxidation: their importance in diabetes mellitus].
Actis Dato SM; Rebolledo OR
Medicina (B Aires); 2000; 60(5 Pt 1):645-56. PubMed ID: 11188909
[TBL] [Abstract][Full Text] [Related]
28. Advanced glycation in health and disease: role of the modern environment.
Vlassara H
Ann N Y Acad Sci; 2005 Jun; 1043():452-60. PubMed ID: 16037266
[TBL] [Abstract][Full Text] [Related]
29. The emerging challenge in diabetes: the "metabolic memory".
Ceriello A
Vascul Pharmacol; 2012; 57(5-6):133-8. PubMed ID: 22609133
[TBL] [Abstract][Full Text] [Related]
30. Endogenous secretory receptor for advanced glycation end-products and cardiovascular disease in end-stage renal disease.
Nishizawa Y; Koyama H
J Ren Nutr; 2008 Jan; 18(1):76-82. PubMed ID: 18089449
[TBL] [Abstract][Full Text] [Related]
31. Advanced glycation end products and diabetic foot disease.
Huijberts MS; Schaper NC; Schalkwijk CG
Diabetes Metab Res Rev; 2008; 24 Suppl 1():S19-24. PubMed ID: 18442180
[TBL] [Abstract][Full Text] [Related]
32. Carbonyl stress and diabetic complications.
Miyata T; Ishikawa N; van Ypersele de Strihou C
Clin Chem Lab Med; 2003 Sep; 41(9):1150-8. PubMed ID: 14598864
[TBL] [Abstract][Full Text] [Related]
33. Receptor for advanced glycation end products and the cardiovascular complications of diabetes and beyond: lessons from AGEing.
Yan SF; Yan SD; Herold K; Ramsamy R; Schmidt AM
Endocrinol Metab Clin North Am; 2006 Sep; 35(3):511-24, viii. PubMed ID: 16959583
[TBL] [Abstract][Full Text] [Related]
34. Diabetic neuropathy and oxidative stress.
Pop-Busui R; Sima A; Stevens M
Diabetes Metab Res Rev; 2006; 22(4):257-73. PubMed ID: 16506271
[TBL] [Abstract][Full Text] [Related]
35. [Role of oxidative stress in diabetic vascular complications].
Inoguchi T; Takayanagi R
Fukuoka Igaku Zasshi; 2008 Mar; 99(3):47-55. PubMed ID: 18536327
[No Abstract] [Full Text] [Related]
36. Mechanisms of disease: Pathway-selective insulin resistance and microvascular complications of diabetes.
Groop PH; Forsblom C; Thomas MC
Nat Clin Pract Endocrinol Metab; 2005 Dec; 1(2):100-10. PubMed ID: 16929378
[TBL] [Abstract][Full Text] [Related]
37. Advanced glycation endproducts: what is their relevance to diabetic complications?
Ahmed N; Thornalley PJ
Diabetes Obes Metab; 2007 May; 9(3):233-45. PubMed ID: 17391149
[TBL] [Abstract][Full Text] [Related]
38. Advanced glycoxidation products and impaired diabetic wound healing.
Peppa M; Stavroulakis P; Raptis SA
Wound Repair Regen; 2009; 17(4):461-72. PubMed ID: 19614910
[TBL] [Abstract][Full Text] [Related]
39. Inhibitors of advanced glycation end products (AGEs): potential utility for the treatment of cardiovascular disease.
Yamagishi S; Nakamura K; Matsui T; Ueda S; Noda Y; Imaizumi T
Cardiovasc Ther; 2008; 26(1):50-8. PubMed ID: 18466420
[TBL] [Abstract][Full Text] [Related]
40. Accumulation of advanced glycation end products and chronic complications in ESRD treated by dialysis.
Meerwaldt R; Zeebregts CJ; Navis G; Hillebrands JL; Lefrandt JD; Smit AJ
Am J Kidney Dis; 2009 Jan; 53(1):138-50. PubMed ID: 19036487
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
